Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Aims: Two single‐dose studies were conducted in J apan and E urope to compare the pharmacokinetic ( PK ) and pharmacodynamic ( PD ) profiles of new insulin glargine 300 U/ml ( Gla‐300 ) and insulin glargine 100 U/ml ( Gla‐100 ) in people with type 1 diabetes mellitus. Methods: In two double‐blind, randomized, crossover studies, 18 J apanese participants (aged 20–65 years) and 24 E uropean participants (aged 18–65 years) with glycated haemoglobin levels ≤9.0% (≤75 mmol/mol) received single subcutaneous doses of Gla‐300 , 0.4, 0.6 and 0.9 U/kg (0.9 U/kg in the E uropean study only), and Gla‐100 , 0.4 U/kg. A 36‐h euglycaemic clamp procedure was performed after each dosing. Results: The serum insulin glargine concentration ( INS ) and glucose infusion rate ( GIR ) developed more gradually into more constant and prolonged profiles with Gla‐300 than with Gla‐100 . In support of this, the times to 50% of glargine exposure and insulin activity were longer for all Gla‐300 doses than for Gla‐100 during the 36‐h clamp period, indicating a more evenly distributed exposure and metabolic effect beyond 24 h. Exposure to insulin glargine and glucose utilization were lower with the 0.4 and 0.6 U/ml Gla‐300 doses in both studies compared with the 0.4 U/ml Gla‐100 dose. Glucose‐lowering activity was detected for up to 36 h with all doses of Gla‐300 . Conclusions: Single‐dose injections of Gla‐300 present more constant and prolonged PK and PD profiles compared with Gla‐100 , maintaining blood glucose control for up to 36 h in euglycaemic clamp settings in J apanese and E uropean participants with type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s5 · Cited by 2,689
Seino, Y., Nanjo, K., Tajima, N., Kadowaki, T., Kashiwagi, A., Araki, E., Ito, C., Inagaki, N., Iwamoto, Y., Kasuga, M., et al. (2010) · Diabetology International · doi:10.1007/s13340-010-0006-7 · Cited by 614
Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-0990 · Cited by 274
Pieber, T. R., Eugène-Jolchine, I., & Derobert, E. (2000) · Diabetes Care · doi:10.2337/diacare.23.2.157 · Cited by 224
Cited by
Visentin, R., Schiavon, M., Giegerich, C., Klabunde, T., Man, C. D., & Cobelli, C. (2019) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2019.2897851 · Cited by 22
“We refer to [7], [8],”
MethodResultUnderstanding concentrated insulins: a systematic review of randomized controlled trials
Ovalle, F., Segal, A. R., Anderson, J. E., Cohen, M. R., Morwick, T. M., & Jackson, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1409426 · Cited by 16
Visentin, R., Schiavon, M., Giegerich, C., Klabunde, T., Man, C. D., & Cobelli, C. (2018) · 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2018.8513234 · Cited by 9
“NCT01195454) [6], a 36-h euglycemic clamp was performed in 24 T1D subjects receiving a single sc dose of Gla-100, 0.”
MethodXie, P., He, X., Gao, X., Shuai, M., Schmider, W., Jiang, A., Yang, N., & Shi, A. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01434-0 · Cited by 2
Metadata
- Authors
- Shiramoto, M., Eto, T., Irie, S., Fukuzaki, A., Teichert, L., Tillner, J., Takahashi, Y., Koyama, M., Dahmen, R., Heise, T., & Becker, R. H. A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-12-22
- Volume
- 17
- Issue
- 3
- Pages
- 254-260
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2065510740
- Cited by
- 95
- References
- 4
- FWCI
- 9.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.